Tue October 4th, 2016
Global whole exome sequencing market was valued at $326.6 million in 2013 and is expected to grow at a CAGR of 22.0% from 2013 to 2018, to reach $884.1 million by 2018.
Download The Free PDF Brochure@ http://bit.ly/2dXezUB Whole Exome Sequencing (WES) is next-generation technology used for strategically sequencing the coding region of the genome, i.e. the exon. The exome, which is the total of all exons of an organism, represents only 1-2% of the total genome and is actually converted into proteins after translation. It is responsible for the occurrence of nearly 85% of genetic diseases. Whole exome sequencing is widely used for identifying and determining genetic variants responsible for various diseases such as Miller Syndrome and Alzheimer's disease. The rapidly decreasing costs of sequencing, adoption of WES technology by new consumers, strategic alliances amongst key players and research institutes, and increase in use of WES technology for new scientific applications are driving the demand for this technology. The most important factor increasing the preference of WES over whole-genome sequencing is its low-cost sequencing capability. However, a lack of skilled professionals and high reliability on government grants are some of the factors hindering the growth of the WES market.